Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748517 | 0.87 | — | — | |
| SCHEMBL13059465 | 0.83 | MGLL (0.31) | MGLL | |
| SCHEMBL27827821 | 0.80 | PARL (0.34) | MGLL | |
| SCHEMBL14424322 | 0.79 | MGLL (0.34) | MGLLKMT2A | |
| SCHEMBL8768378 | 0.78 | MGLL (0.34) | MGLL | |
| SCHEMBL24486741 | 0.78 | MT-CO2 (0.32) | — | |
| SCHEMBL7942332 | 0.78 | EPHX1 (0.38) | KMT2APOLB | |
| SCHEMBL18812101 | 0.78 | KDM4E (0.36) | MGLLKMT2APOLB | |
| SCHEMBL11710142 | 0.78 | MAPT (0.34) | MGLL | |
| SCHEMBL17634441 | 0.77 | CHRM2 (0.32) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119526872-A | Non-cured rubber asphalt waterproof coiled material and preparation method thereof | 广东国鹰新材料有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-117820239-A | Novel CSF1R inhibitor and preparation method and application thereof | 四川大学华西医院 | 2024-04-05 | — | — | CN | claimed |
| US-8232392-B2 | Process for preparing temozolomide | CHEMI S.P.A. (IT) | 2012-07-31 | — | — | US | claimed |
| US-20100036121-A1 | Process for preparing temozolomide | CHEMI S.P.A. (IT) | 2010-02-11 | — | — | US | claimed |
| EP-2151442-A2 | Process for preparing temozolomide | Chemi SPA (IT) | 2010-02-10 | — | — | EP | claimed |
| US-6245478-B1 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-12 | — | — | US | claimed |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260138951-A1 | TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION | JNANA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12479820-B2 | Pyridin-3-yl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
| WO-2006018435-A1 | BENZOTHIENOPYRIDINES FOR USE AS INHIBITORS OF EG5 KINESIN | ALTANA PHARMA AG (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-6245478-B1 | Resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-12 | — | — | US | disclosed |
| US-4003912-A | PREEMERGENCE HERBICIDES | MONSANTO COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | CHRM1 2881/4885MGLL 1894/4885KMT2A 1358/4885 |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | CHRM1 4756/4885MGLL 1245/4885KMT2A 3364/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CHRM1 1675/4885MGLL 2339/4885KMT2A 3839/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | CHRM1 436/4885MGLL 1056/4885KMT2A 4450/4885 |
| US-20260138951-A1 | TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION | SLC6A19, SLC6A9, SLC2A9 | CHRM1 2672/4885MGLL 1230/4885KMT2A 930/4885 |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | MMP13, MMP3, MMP11 | CHRM1 4702/4885MGLL 1758/4885KMT2A 1224/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | CHRM1 631/4885MGLL 4536/4885KMT2A 2861/4885 |
| US-20100036121-A1 | Process for preparing temozolomide | MGMT, NNMT, NOS2 | CHRM1 2915/4885MGLL 4191/4885KMT2A 248/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | CHRM1 1032/4885MGLL 862/4885KMT2A 2575/4885 |
| US-12479820-B2 | Pyridin-3-yl derivatives | LPAR1, LPAR3, LPAR2 | CHRM1 12/4885MGLL 274/4885KMT2A 2179/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | CHRM1 2854/4885MGLL 3775/4885KMT2A 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.